« Previous
Next »
Titles
- Addressing the direct care workforce shortage: a bipartisan call to action1
- Antiviral drugs: Economic incentives and strategies for pandemic preparedness : report to congressional committees1
- Assessing the credibility of computational modeling and simulation in medical device submissions: guidance for industry and Food and Drug Administration staff1
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- CARES Act: experts identified safeguards to help selected HHS agencies protect against potential political interference : report to congressional requesters1
- CDC has improved the nursing home reporting process for COVID-19 Data in NHSN, but challenges remain1
- CDC provided oversight and assistance: however, ELC recipients still faced challenges in implementing COVID-19 screening testing programs1
- CDC’S Vaccines for Children program recipients did not conduct site visits at some providers as required1
- CDC’s internal control weaknesses led to its initial COVID-19 test kit failure, but CDC ultimately created a working test kit1
- CMS can do more to leverage Medicare claims data to identify unreported incidents of potential abuse or neglect1
- COVID-19 Provider Relief Fund: HRSA continues to recover remaining payments due from providers : report to congressional committees1
- COVID-19: USAID plans to share lessons learned from efforts to meet global vaccination goal : report to congressional addressees1
- Cleaner health care: hospital emissions mitigation1
- Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry1
- Defense health care: DOD assessment needed to ensure TRICARE behavioral health coverage goals are being met : report to congressional committees1
- Development and licensure of vaccines to prevent COVID-19: guidance for industry1
- Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use authorization: guidance for industry1
- Digital health technologies for remote data acquisition in clinical investigations: guidance for industry, investigators, and other stakeholders1
- Direct-to-consumer prescription drug advertisements: presentation of the major statement in a clear, conspicuous, and neutral manner in advertisements in television and radio format final rule : questions and answers : guidance for industry1
- Enforcement policy for certain supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) submissions: guidance for industry and Food and Drug Administration staff1